Publicacións en colaboración con investigadores/as de University of Paris-Saclay (2)

2021

  1. Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

    Journal of Autism and Developmental Disorders, Vol. 51, Núm. 8, pp. 2959-2972

  2. Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) (Journal of Autism and Developmental Disorders, (2021), 51, 8, (2959-2972), 10.1007/s10803-020-04709-8)

    Journal of Autism and Developmental Disorders